actemra 400 mg/20 ml koncentrat za rastvor za infuziju
roche d.o.o.roche ltd. - tocilizumab - koncentrat za rastvor za infuziju - 400 mg/20 ml - 20 ml koncentrata za rastvor za infuziju sadrži: 400 mg tocilizumaba ( 20 mg/ml )
avastin 100 mg/4 ml koncentrat otopine za infuziju
roche d.o.o.roche ltd. - bevacizumab - koncentrat otopine za infuziju - 100 mg/4 ml - 4 ml koncentrata za otopinu za infuziju sadrži: 100 mg bevacizumaba (25 mg/ml)
avastin 400 mg/16 ml koncentrat otopine za infuziju
roche d.o.o.roche ltd. - bevacizumab - koncentrat otopine za infuziju - 400 mg/16 ml - 16 ml kocentrata za otopinu za infuziju sadrži: 400 mg bevacizumaba (25 mg/ml)
recormon 2000 i.j./0.3 ml rastvor za injekciju
roche d.o.o.roche ltd. - epoetin beta - rastvor za injekciju - 2000 i.j./0.3 ml - 0,3 ml rastvora za injekciju sadrži: 2000 i.u. epoetin beta (humani rekombinantni eritropoetin)
tecentriq 60 mg/1 ml koncentrat za otopinu za infuziju
roche d.o.o.roche ltd. - atezolizumab - koncentrat za otopinu za infuziju - 60 mg/1 ml - 14 ml koncentrata za otopinu za infuziju sadrži: 840 mg atezolizumaba (60 mg/ml)
evrysdi
roche registration gmbh - risdiplam - mišićna atrofija, kralješnica - ostali lijekovi za poremećaje mišićno-koštanog sustava - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresivi - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
herceptin 150 mg/1 viala prašak za koncentrat za rastvor za infuziju
roche d.o.o.roche ltd. - trastuzumab - prašak za koncentrat za rastvor za infuziju - 150 mg/1 viala - 1 bočica sa praškom za koncentrat za rastvor za infuziju sadrži: 150 mg trastuzumab
polivy 140 mg/1 bočica prašak za koncentrat za otopinu za infuziju
roche d.o.o.roche ltd. - polatuzumab ведотин - prašak za koncentrat za otopinu za infuziju - 140 mg/1 bočica - 1 bočica od 20 ml sadrži: 140 mg polatuzumab vedotina
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - imuni serumi i homologna, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. pogledajte odjeljke 4. 4 i 5.